Regulation
Cepheid’s 13-Pathogen Respiratory Panel Gains IVDR CE Mark

Key PointsCepheid's respiratory panel now carries IVDR CE marking and shipments to accepting…
View more
- Cepheid's respiratory panel now carries IVDR CE marking and shipments to accepting countries are planned soon.
- The multiplex test detects many viral and bacterial targets from a single swab on existing GeneXpert systems.
- Cepheid frames the panel as supporting treatment decisions and responsible antibiotic use rather than stand-alone diagnosis.
Cepheid, a Danaher company, announced on November 10, 2026 that its Xpert Respiratory Panel had achieved CE marking under the in vitro medical device regulation (IVDR). The multiplex PCR test is designed to detect 13 common viral and bacterial respiratory pathogens from one nasopharyngeal swab sample, and shipments to countries accepting the CE mark are planned to begin in the coming weeks.
The panel is intended to aid in the diagnosis of suspected infectious respiratory tract infection in conjunction with other clinicopathological factors. Its role is to add pathogen information to a broader clinical assessment, not to serve as a stand-alone diagnosis. Cepheid says identifying multiple viral and bacterial respiratory infections can support informed treatment decisions and responsible antibiotic use.
Test Menu and GeneXpert Workflow
The targets are adenovirus, coronavirus, SARS-CoV-2, human metapneumovirus, human rhinovirus/enterovirus, human parainfluenza, influenza A, influenza B, respiratory syncytial virus, Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae and Chlamydia pneumoniae.
That breadth addresses a common diagnostic difficulty: acute respiratory tract infections can produce overlapping, nonspecific symptoms such as fever, cough and sore throat even though different viral or bacterial pathogens are responsible. Distinguishing among those possible causes can help inform clinical assessment.
The panel runs on existing GeneXpert systems and expands a respiratory portfolio that already includes low- and mid-plex options. Cepheid reports that it requires less than one minute of hands-on time and provides on-demand answers. The company’s test-selection approach spans targeted single-pathogen tests, mid-plex panels and broader syndromic respiratory panels on the same system.
“As healthcare systems across Europe prepare for the upcoming respiratory season, the ability to match the right test to the right patient is more important than ever,” said Christoph Martinaud, Senior Director, Medical Affairs EMEA at Cepheid.
European Context and U.S. Regulatory Chronology
In its November 20, 2025 assessment, the European Centre for Disease Prevention and Control said influenza, SARS-CoV-2 and respiratory syncytial virus all contribute to winter pressure on healthcare systems in the European Union and European Economic Area. In a typical season, influenza causes up to 50 million symptomatic cases and 15,000 to 70,000 deaths annually in the European population.
The IVDR marking follows Cepheid’s September 29, 2026 announcement that the U.S. Food and Drug Administration had cleared the same panel. At that time, the company said shipments to U.S. customers would begin in the coming weeks. The two actions establish separate regulatory milestones for the same assay rather than introducing different respiratory panels.
For laboratories, the practical consequence is a broader respiratory menu on an existing platform. For Cepheid, the commercial milestone now shifts from regulatory marking to execution of the planned shipments, which will determine when the panel becomes available to customers in countries accepting the CE mark.












